131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors

Seminars in Nuclear Medicine

Volumn 40, Issue 2, 2010, Pages 153-163

  Grünwald, Frank ^a   Ezziddin, Samer ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; INTERFERON; ISOTRETINOIN; MELPHALAN; RESERPINE; SOMATOSTATIN DERIVATIVE; TOPOTECAN; VINBLASTINE; VINCRISTINE; (3 IODOBENZYL)GUANIDINE;

ADJUVANT THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CARCINOID; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UPTAKE; DRUG WITHDRAWAL; ENVIRONMENTAL RADIOACTIVITY; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LEUKOPENIA; MERKEL CELL TUMOR; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL CARCINOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON; RADIATION EXPOSURE; RADIATION PROTECTION; RADIATION SAFETY; RADIOSENSITIZATION; REVIEW; THROMBOCYTOPENIA; THYROID CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; ANIMAL; MULTIMODALITY CANCER THERAPY;

3-IODOBENZYLGUANIDINE; ANIMALS; COMBINED MODALITY THERAPY; HUMANS; NEUROBLASTOMA; NEUROENDOCRINE TUMORS;

EID: 74849100940     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.11.004     Document Type: Review

References (80)

1. Schilling F.H., Spix C., Berthold F., et al. Neuroblastoma screening at one year of age. N Engl J Med 346 (2002) 1047-1053
2. Stiller C.A., and Parkin D.M. International variations in the incidence of neuroblastoma. Int J Cancer 52 (1992) 538-543
3. Brodeur M., and Castleberry R.P. Neuroblastoma. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and Practice of Pediatrics (1997), Lippincot-Raven, Philadelphia, PA 761-797
4. Matthay K.K. Neuroblastoma. In: Pochedly C. (Ed). Neoplastic Diseases in Childhood (1994), Harwood, Chur, Switzerland 735-778
5. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341 (1999) 1165-1173
6. London W.B., Castleberry R.P., Matthay K.K., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23 (2005) 6459-6465
7. Marris J.M., Hogarty M.D., Bagatell R., et al. Neuroblastoma. Lancet 369 (2007) 2106-2120
8. Brodeur M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 (1993) 1466-1477
9. Wieland D.M., Wu J.L., Brown L.E., et al. Radiolabeled adrenergi neuron-blocking agents: Adrenomedullary imaging with [131-I]iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
10. McEwan A.J., Shapiro B., Sisson J.C., et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15 (1985) 132-153
11. Hattner R.S., Huberty J.P., Engelstad B.L., et al. Localization of m-iodo (131-I) benzylguanidine in neuroblastoma. AJR Am J Roentgenol 143 (1984) 373-374
12. Leung A., Shapiro B., Hattner R., et al. Specificity of radioiodinated MIBG for neutral crest tumors in childhood. J Nucl Med 38 (1997) 1352-1357
13. Shimada H., Ambros I.M., Dehner L.P., et al. The international neuroblastoma pathology classification (the Shimada system). Cancer 86 (1999) 364-372
14. Attiyeh E.F., London W.B., Mosse Y.P., et al. Childrens Oncology Group: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353 (2005) 2243-2253
15. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340 (1999) 1954-1961
16. Zaplatnikov K., Menzel C., Döbert N., et al. Case report: Drug interference with MIBG uptake in patient with metastatic paraganglioma. Br J Radiol 77 (2004) 525-527
17. Wafelman A.R., Nortier Y.L., Rosing H., et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun 16 (1995) 767-772
18. Ehninger G., Klingebiel T., Kumbier I., et al. Stability and pharmacokinetics of m-131I-iodobenzylguanidine in patients. Cancer Res 47 (1987) 6147-6149
19. Klingebiel T., Treuner J., Ehninger G., et al. 131 I-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological, and dosimetric aspects. Cancer Chemother Pharmacol 25 (1989) 143-148
20. Dubois S.G., and Matthay K.K. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35 suppl 1 (2008) S35-S48
21. Sudbrock F., Eschner W., Schmidt M., et al. Dosimetry for therapeutic treatment of neuroblastoma by 131I-MIBG. Nuklearmedizin 6 (2006) 254-261
22. Garaventa A., Guerra P., Arrighini A., et al. Treatment of advanced neuroblastoma with 131I meta-iodobenzylguanidine. Cancer 67 (1991) 922-928
23. Garaventa A., Bellagamba O., Lo Piccolo M.S., et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer 81 (1999) 1378-1384
24. Hoefnagel C.A., Voute P.A., de Kraker J., et al. 131I-metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 35 (1991) 202-206
25. Klingebiel T., Bader P., Bares R., et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot trial. Eur J Cancer 34 (1998) 1398-1402
26. Klingebiel T., Berthold F., Treuner J., et al. (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial. Med Pediatr Oncol 19 (1991) 84-88
27. Lashford L.S., Lewis I.J., Fielding S.L., et al. Phase I/II trial of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10 (1992) 1889-1896
28. Matthay K.K., DeSantes K., Hasegawa B., et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16 (1998) 229-236
29. Sisson J.C., Shapiro B., Hutchinson R.J., et al. Survival of patients with neuroblastomas treated with 125I MIBG. Am J Clin Oncol 19 (1996) 144-148
30. Troncone L., Rufini V., Montemaggi P., et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med 16 (1990) 325-335
31. Schmidt M., Simon T., Hero B., et al. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma?. Nuklearmedizin 45 (2006) 145-151
32. Menzel C., Graichen S., Berner U., et al. Monitoring the efficacy of iodine-131 MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 30 (2003) 37-40
33. Taggart D., Dubois S., and Matthay K.K. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 52 (2008) 403-418
34. De Kraker J., Hoefnagel K.A., Verschuur A.C., et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44 (2008) 551-556
35. Mastrangelo S., Tornesello A., Diociaiuti L., et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 84 (2001) 460-464
36. Miano M., Garaventa A., Pizzitola M.R., et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 27 (2001) 571-574
37. Yanik G.A., Levine J.E., Matthay K.K., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20 (2002) 2142-2149
38. Gaze M.N., Chang Y.C., Flux G.D., et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20 (2005) 195-199
39. Matthay K., Quach A., Huberty J., et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 27 (2009) 1020-1025
40. Koral K.F., Huberty J.P., Frame B., et al. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging 35 (2008) 2105-2112
41. Voute P.A., van der Kleij A.J., De Kraker J., et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31A (1995) 596-600
42. Diehl M., Fußhoeller G., Menzel C., et al. Hyperbaric oxygen to intensify 131-I-MIBG therapy in refractory neuroblastoma stage 4. Nuklearmedizin 6 (2004) N77-N80
43. Mastrangelo S., Tornesello A., Lasorella A., et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neuro Oncol 31 (1997) 153-158
44. Mastrangelo R., Tornesello A., Riccardi R., et al. A new approach in the treatment of stage IV neuroblastoma using a combination of 131-I-metaiodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 31A (1995) 606-611
45. Sudbrock F., Boldt F., Kobe C., et al. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Nuklearmedizin 48 (2009) 17-25
46. Solanki K.K., Bomanji J., Moyes J., et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13 (1992) 513-521
47. Pasieka J.L., McEwan A.J., and Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136 (2004) 1218-1226
48. Sywak M.S., Pasieka J.L., McEwan A.J.B., et al. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 28 (2004) 1157-1162
49. Taal B.G., Hoefnagel C.A., Valdes Olmos R.A., et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14 (1996) 1829-1838
50. Mukherjee J.J., Kaltsas G.A., Islam N., et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-MIBG]. Clin Endocrinol (Oxf) 55 (2001) 47-60
51. Bomanji J.B., Wong W., Gaze M.N., et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 15 (2003) 193-198
52. Safford S.D., Coleman R.E., Gockerman J.P., et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101 (2004) 1987-1993
53. Safford S.D., Coleman R.E., Gockerman J.P., et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134 (2003) 956-962 discussion 962-963
54. Nwosu A.C., Jones L., Vora J., et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 98 (2008) 1053-1058
55. Gedik G., Hoefnagel C., Bais E., et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35 (2008) 725-733
56. Gonias S., Goldsby R., Matthay K.K., et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27 (2009) 4162-4168
57. Fassnacht M., Kreissl M.C., Weismann D., et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123 (2009) 117-141
58. Forrer F., Riedweg I., Maecke H.R., et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52 (2008) 334-340
59. Chrisoulidou A., Kaltsas G., Ilias I., et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14 (2007) 569-585
60. Loh K.C., Fitzgerald P.A., Matthay K.K., et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 20 (1997) 648-658
61. Hoefnagel C.A. Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours. Eur J Nucl Med 21 (1994) 561-581
62. Gao Z., Biersack H.-J., Ezziddin S., et al. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 130 (2004) 649-656
63. Kaltsas G.A., Mukherjee J.J., and Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol 12 suppl 2 (2001) S47-S50
64. Castellani M.R., Seregni E., Maccauro M., et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: Is there still a role?. Q J Nucl Med Mol Imaging 52 (2008) 430-440
65. Buscombe J.R., Cwikla J.B., Caplin M.E., et al. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26 (2005) 969-976
66. Ezziddin S., Logvinski T., Ahmadzadehfar H., et al. Update zur I-131-MIBG-Therapie beim fortgeschrittenen Karzinoid: Langzeitüberleben und Toxizität bei Anwendung von 11.1 GBq pro Zyklus. Nuklearmedizin (2008) 1-2
67. Taal B.G., Hoefnagel C.A., Valdes Olmos R.A., et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14 (1996) 1829-1838
68. Ezziddin S., Logvinski T., Yong-Hing C., et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 47 (2006) 223-233
69. Forrer F., Waldherr C., Maecke H.R., et al. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26 (2006) 703-707
70. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
71. Madsen M.T., Bushnell D.L., Juweid M.E., et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med 47 (2006) 660-667
72. Brogsitter C., Pinkert J., Bredow J., et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med 46 (2005) 2112-2116
73. Brogsitter C., Pinkert J., Bredow J., et al. Verbesserte intratumorale Retention in neuroendokrinen Tumoren nach intraarterieller Applikation von 131I-MIBG. Nuklearmediziner 31 (2008) 132-136
74. Sisson J.C., Shapiro B., Shulkin B.L., et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 22 (1999) 364-370
75. Zuetenhorst J.M., Valdes Olmos R.A., Muller M., et al. Interferon and meta-iodobenzylguanidine combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer 11 (2004) 553-561
76. Taal B.G., Hoefnagel C., Boot H., et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 11 (2000) 1437-1443
77. Zuetenhorst H., Taal B.G., Boot H., et al. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidine (MIBG): Pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol 11 (1999) 1157-1164
78. Vaidyanathan G., and Zalutsky M.R. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot 44 (1993) 621-628
79. Mairs R.J., and Boyd M. Optimizing MIBGtherapy of neuroendocrine tumors: Preclinical evidence of dose maximization and synergy. Nucl Med Biol 35 suppl 1 (2008) S9-S20
80. Owens J., Bolster A.A., Prosser J.E., et al. No-carrier-added 123I-MIBG: An initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 21 (2000) 437-440